Chronic lymphocytic leukaemia trials in Poland

In Poland 36 Also abroad 308

36 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Study to Test How Safe, Effective and How the Body Responds to the Combination of Mosunetuzumab and Pirtobrutinib Together to Treat Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Where
Cracow, Lublin, Wroclaw
Age
18 years and over
People
22 worldwide
Run by
F. Hoffmann-La Roche AG
See details and how to join2024-514152-32-00 · EU 2024-514152-32-00
Phase 1Taking people
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Where
Katowice, Krakow, Lublin, Skórzewo, Warsaw, Wroclaw
Age
18 years and over
People
572 worldwide
Run by
Nurix Therapeutics, Inc.
See details and how to joinNCT05131022 · EU 2023-510541-25-00
Phase 4Not yet taking people in Poland
Phase IV VR in relapsed CLL – Polish experience
Where
Bydgoszcz, Lodz, Lublin, Warsaw, Wroclaw
Age
18 years and over
People
36
Run by
Uniwersytet Medyczny W Lublinie
See details and how to join2025-524795-35-00 · EU 2025-524795-35-00
Phase 3Taking people
Global Trial in APG2575 for Patients With CLL/SLL
Where
Bydgoszcz, Cracow, Lodz, Skorzewo
Age
18 years to 99 years
People
400 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00
Phase 3Taking people
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Where
Bydgoszcz, Cracow, Gdansk, Gdynia, Katowice, Legnica, Lublin, Opole, Skorzewo, Slupsk, Walbrzych, Warsaw, Wroclaw
Age
18 years and over
People
250 worldwide
Run by
Dizal Pharmaceuticals
See details and how to joinNCT07139873 · EU 2025-522669-32-00
Phase 1/2Not yet taking people in Poland
A study aimed at Optimise and Personalise Immunological Therapy of relapsed chronic lymphocytic leukaemia patients (OPTIC)
Where
Bydgoszcz, Lodz, Lublin, Warsaw, Wroclaw
Age
18 years and over
People
36
Run by
Uniwersytet Medyczny W Lublinie
See details and how to join2024-513917-11-01 · EU 2024-513917-11-01
Phase 4Taking people
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Where
Krakow, Warsaw
Age
18 years and over
People
787 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06876649
Phase 4Taking people
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Where
Krakow, Warsaw
Age
18 years and over
People
279 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06876662
Phase 1Taking people
Study of SGR-1505 in Mature B-Cell Neoplasms
Where
Gdansk, Lodz, Warsaw
Age
18 years and over
People
98 worldwide
Run by
Schrödinger, Inc.
See details and how to joinNCT05544019 · EU 2023-505204-34-00
Phase 3Taking people
AVO-CLL: a phase III multicenter, randomized, open-label, clinical trial comparing efficacy and safety of acalabrutinib in combination with obinutuzumab versus venetoclax in combination with obinutuzumab in the first-line treatment of newly diagnosed patients with chronic lymphocytic leukemia
Where
Bia?ystok, Gdansk, Legnica, Łódź, Walbrzych, Warsaw, Wroc?aw
Age
18 years and over
People
72
Run by
Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
See details and how to join2023-508423-13-00 · EU 2023-508423-13-00
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Gdansk, Gliwice, Krakow, Wroclaw
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394